TO THE EDITOR
Currently, high-dose chemotherapy and autologous peripheral stem cell transplantation (HD/APSCT) are considered the treatment of choice for multiple myeloma (MM) patients younger than 60 years resulting in longer-lasting disease-free survival and increased remission rate as compared to conventional chemotherapy. Recent publications showed that these autografted myeloma patients present a severe defect in T-cell function early after transplantation (p12 days) and a decreased CD4 T-cell count lasting approximately 18 months. 1, 2 As HD/ APSCT cannot be considered curative, several groups tried to augment the beneficial effects of this treatment by vaccinations with tumor antigens. In MM patients, monoclonal immunoglobulins with specific antigenic determinants, the idiotype (Id), can serve as a target for active immunotherapy. However, the results of these vaccination trials have been rather disappointing as only sporadic cases showed tumor regression and 17-40% Idspecific T-cell responses. 3, 4 To elucidate which treatment or clinical parameters affect the recovery of cellular in vitro immune function -a prerequisite for effective tumor vaccinations -after MM therapy, we performed lymphocyte transformation tests (LTT) with samples of 61 MM patients receiving various therapeutic regimens (Table 1) , compared the results with those from 100 age-and sex-matched healthy controls, and subjected the data from MM patients to multinomial regression analysis.
Firstly, cellular in vitro responses toward all mitogens tested and those recall antigens inducing strong cellular responses except for CMV 5 were significantly (Po0.01) reduced in MM patients as compared to healthy controls ( Figure 1 ). Interestingly, positive LTT reactions (counts per minute (cpm) increment 40) toward cytomegalovirus (CMV) antigen were significantly more frequent in MM patients as compared to controls (83 vs 66%, Po0.05) but the strength of positive reactions was diminished in the patients cohort (543 vs 2,019, data represent median cpm increment values, Po0.01). Secondly, within 12 months after HD/APSCT, responses to mitogens and recall antigens were significantly (Po0.05) below those 412 months post-HD/ APSCT and those after conventional chemotherapy, or no chemotherapy ( Figure 1 ).
To consider in combination the effect of treatment or clinical parameters on cellular in vitro immune function, all LTT results in MM patients (n ¼ 169 blood samples tested) were subjected to multinomial logistic regression analysis. This analysis was performed for individual mitogens, recall antigens, and the cumulative antigen score, which represents the proliferative response capacity toward 12 recall antigens. 5 Results of the regression analysis indicated that the application of HD/APSCT within the last 12 months was by far the most prominent factor affecting cellular in vitro reactivity (Po0.05) followed by decreasing impact of the application (vs no application) of HD/APSCT, disease status (complete remission, partial remission, progressive disease), relapse, and thalidomide treatment (which was used as maintenance therapy). These parameters could all be defined as suppressive or, in the case of the disease status, LTT reactions were lowest in the progressive disease group. Furthermore, cellular in vitro reactions decreased with increasing relapse rate. On the contrary, no significant effect of conventional chemotherapy or age could be detected by regression analysis. Apart from this multinomial analysis which was performed in all samples, two matched pairs of MM patients in complete remission treated by chemotherapy within the last 12 months were compared (median follow-up in both groups: 3 months): LTT results in the HD/APSCT group (n ¼ 27) were significantly below those from the conventional chemotherapy group (n ¼ 11), for example, PHA-LTT: 20,267 vs 50,447 cpm increment, Po0.05. Spearman's correlation analysis (n ¼ 71), which accounts for individual variables, confirmed the results of the regression analysis in HD/APSCT patients. The time after HD/APSCT was significantly correlated with reactions toward mitogens, the cumulative antigen score (Po0.001 each) ( Figure  2a , b), and reactions toward those eight recall antigens inducing the strongest cellular reactions except for CMV (Po0.05). In contrast, we could not observe a time dependency of cellular in vitro reactions in patients after conventional chemotherapy (n ¼ 73, Figure 2c, d) . Moreover, the evaluation of only the first value in each patient corroborated our results in the HD/APSCT and conventional chemotherapy group. Besides, LTT results did not differ significantly in patients with indolent myeloma vs those prior to chemotherapy, nor were they dependent on the number of previous chemotherapy cycles or on the type of secretory myeloma (14 Bence-Jones, 15 IgA, and 29 IgG, together 162 samples). Interestingly, we observed a trend toward increased reactions in asecretory vs secretory types (eg, PHA-LTT: 177,764 vs 76,302 cpm increment). The size of this asecretory group (seven blood samples procured from three subjects) precluded statistical analysis.
In summary, the impairment of T-cell response capacity in MM patients is dependent on HD/APSCT therapy (in particular, within the first 12 months), status of disease, relapse, and thalidomide treatment. The effect of thalidomide on cellular in vitro immune function was described as rather heterogeneous. 6 While this drug enhanced mitogen-stimulated cells' ability to synthesize IL-2, it suppressed PHA-induced [H3]-thymidine incorporation. Thus, our findings are concordant with this recent publication. The influence of conventional chemotherapy seems to be weak as it was undetectable by multinomial regression analysis. Additionally, the myeloma type (asecretory vs secretory) could potentially have an impact on cellular in vitro immune function. On the contrary, age had no significant influence. According to our in vitro data, it is likely that patients are susceptible to infectious complications that may be lethal for a prolonged period of time after HD/APSCT. This assumption is in concordance with Terpos et al 7 analyzing survival rates after HD/APSCT and some clinical conditions also considered in our study; they described a tendency for better survival in asecretory vs secretory MM patients and an independence of outcome from age. The underlying disease per se may influence in vitro reactions toward mitogens and recall antigens. This is supported by a study of De Rosa et al 8 describing that infectious complications were significantly increased in MM patients as compared to breast cancer patients, both of whom were receiving HD/APSCT. Furthermore, an increase in the percentage of positive T-cell reactions toward CMV in MM patients as compared to healthy controls is probably due to the high incidence of CMV infection and reactivation in immunocompromised patients. Our data indicate that CMV infection/ reactivation is relevant not only after allogeneic, but also after autologous transplantation. Approaches of tumor vaccinations in MM patients rely on functional T-cells. Interestingly, the fraction of MM patients displaying Id-specific T-cell responses was lower in a study where all patients received autologous transplantation as compared to a trial where only two out of 12 patients were transplanted prior to tumor vaccination (17 vs 40%, respectively). 3, 4 One could speculate that this difference is attributable to the severely impaired lymphocyte function after HD/APSCT. Therefore, therapeutic regimens with reduced toxicity (eg, due to add-back of T-cells collected prior to myeloablative therapy or the introduction of chemotherapyresistance genes into hematopoietic precursor cells) may be helpful, and make the MM patients accessible to immunomodulatory treatment. Up to now, tumor vaccinations were started 2 4 and 3 3 months after chemotherapy, respectively. While prolongation of the interval from HD/APSCT to vaccination could lead to a better recovery of cellular immune function at the time point of vaccination, this option appears risky as a relapse could occur more frequently when waiting too long. To overcome this problem, vaccinations may alternatively be performed early (within 1 month) after transplantation, which could lead to a skewing of the T-cell repertoire toward a specific antigenic target during immune reconstitution. High-dose chemotherapy with autologous blood stem cell support has become the most commonly used treatment in multiple myeloma (MM). Although it has greatly improved event-free and overall survival of patients, the vast majority of them relapse after a variable remission period due to persisting residual tumor cells. Molecular detection of MM tumor cells is based on the immunoglobulin heavy-chain (IgH) gene rearrangement, the sequence of which is unique to each tumor clone and is stable throughout the disease. The wide development of realtime PCR devices offers the possibility to quantify accurately the tumor cells with an allele-specific oligonucleotide (ASO) IgH PCR. The design of individual clono-specific fluorogenic probes is particularly expensive; therefore, germline consensus probe use, along with a patient specific primer, is advisable. But, in MM, the hypermutated status of IgH clonal sequences renders delicate the choice of consensus probes and primers, and is considered as a technical challenge for IgH PCR assay. We have investigated two detection strategies for MM ASO PCR on LightCycler (Roche Applied Science, Meylan, France): with a set of three consensus bi-fluorogenic probes located in the JH region and/or with the DNA intercalating dye SYBR Green I (see supplemental Figure 1 ). Moreover, we developed a new relative quantification method taking advantage of the 'RelQuant' software (Roche Applied Science) with external standards and an internal calibrator sample. In order to evaluate the relevance of our assay in the clinical setting, ASO IgH real-time quantitative (RQ) PCR was applied to determine the tumor load in leukapheresis products, postautograft bone marrow (BM) and peripheral blood (PB) samples from MM patients.
First, IgH consensus PCR was performed under previously described conditions, 1 for 10 MM patients and a lymphoblastoid cell line. Monoclonal purified IgH consensus PCR products were directly sequenced following Applied Biosystems (Courtaboeuf, France) recommendations. The ASO primer was derived
